Dec 27 |
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
|
Dec 26 |
Milestone Pharma falls as FDA rejects new drug application
|
Dec 26 |
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
|
Dec 26 |
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) top owners are individual investors with 52% stake, while 34% is held by institutions
|
Nov 15 |
Milestone Pharmaceuticals Third Quarter 2023 Earnings: US$0.45 loss per share (vs US$0.34 loss in 3Q 2022)
|
Nov 13 |
Milestone Pharmaceuticals GAAP EPS of -$0.35 beats by $0.03
|
Nov 13 |
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
|
Nov 11 |
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
|
Nov 7 |
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR
|